Pregnancy as an Opportunity for Hepatitis C Virus Elimination and Eradication
- PMID: 38150734
- PMCID: PMC10859822
- DOI: 10.4269/ajtmh.23-0629
Pregnancy as an Opportunity for Hepatitis C Virus Elimination and Eradication
Abstract
Since the development of highly effective direct-acting antivirals, the WHO has set a goal of hepatitis C virus (HCV) elimination by 2030. Key to this strategy is increased screening and treatment. Pregnancy and the postpartum period represent a unique time when underserved populations have increased contact with the healthcare system. We propose using antenatal care to maximize case identification, treatment, and prevention. Pregnant individuals are an ideal sentinel population for HCV surveillance. Universal screening in pregnancy can provide population-level data. Once cases are identified, pregnancy presents an opportunity for intervention. Although not currently WHO approved, clinical trials are examining treatment during pregnancy. In the interim, identification of infection during pregnancy allows for optimization of the treatment cascade postpartum. Pregnancy can be used as a time for prevention. Taking advantage of patient engagement and existing infrastructure, pregnancy presents an opportunity to intervene in the fight for HCV eradication.
References
-
- Andes A, Ellenberg K, Vakos A, Collins J, Fryer K, 2020. Hepatitis C virus in pregnancy: a systematic review of the literature. Am J Perinatol 38 ( S 01 ): e1–e13. - PubMed
-
- Polaris Observatory HCV Collaborators , 2022. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol 7: 396–415. - PubMed
-
- Dugan E. et al. , 2021. Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study. Lancet Gastroenterol Hepatol 6: 169–184. - PubMed
-
- Afdhal N. et al. , 2014. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370: 1889–1898. - PubMed
-
- Feld JJ. et al. , 2015. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373: 2599–2607. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
